Second Alzheimer’s antibody approved in the US
By Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
Hit enter after type your search item
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
